Fujifilm Diosynth Biotechnologies Denmark Aps
Biotek Allé 1, 3400 Hillerød, CVR 26060702
Rank Profit for the year
Rank in industry
5/140
"Top 10%"
Rank in Denmark
1,965/334,976
"Top 10%"
Top management - top 3
| Lars Petersen 2 | Director |
Board - top 3
| Martin Edward Meeson 2 | Chairman of board |
| Lars Petersen 2 | Boardmember |
| Takatoshi Ishikawa 1 | Boardmember |
Legal owners - top 3
Rights certificate
Selskabet tegnes af et bestyrelsesmedlem alene. Bestyrelsen kan via fuldmagt bemyndige en person eller flere personer til at tegne på Selskabets vegne.
Company information based on CVR
| Name | Fujifilm Diosynth Biotechnologies Denmark Aps |
|---|---|
| CVR | 26060702 |
| Address | Biotek Allé 1, 3400 Hillerød |
| Industry | Manufacture of pharmaceutical preparations [212000] |
| Established | 01-06-2001 (21 yr) |
| Company type | Limited Corporation (APS) |
| Number of employees | 1059 (man years:1054) |
| Advertising protection | No |
| Auditor | Kpmg P/S since 01-08-2019 |
| Financial statement period | 01-04 to 31-03 |
| Company capital | 390,000 DKK 385,000 DKK (10-04-2008 - 06-05-2008) 380,000 DKK (15-01-2008 - 09-04-2008) 375,000 DKK (01-10-2007 - 14-01-2008) 370,000 DKK (07-08-2007 - 30-09-2007) 365,000 DKK (20-04-2007 - 06-08-2007) |
| Articles of assoc. last | 27-10-2021 |
Member of industries
- Manufacture of pharmaceutical preparationsNACE6 containing 214 comp.
- Manufacture of pharmaceutical preparationsNACE3 containing 214 comp.
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE2 containing 255 comp.
- ManufacturingNACE1 containing 26,897 comp.
Purpose
Selskabets formål er at drive produktions- og handelsvirksomhed og at besidde kapitalandele i andre virksomheder samt at drive anden virksomhed, der efter direktionens skøn er forbunden hermed.
Financial Statement
| 2021 | 2020 | 2018 | |
|---|---|---|---|
| Currency/unit | 000' DKK | 000' DKK | 000' DKK |
| Revenue | 2,727,431 - | 2,039,469 - | 1,417,166 0% |
| Gross Profit | 494,437 - | 65,121 - | 214,188 -11% |
| Profit for the year | 103,550 - | -176,316 - | 253,501 +48% |
| Equity | 3,865,418 - | 3,761,868 - | 3,938,184 +7% |
| Total Assets | 5,848,427 - | 5,508,130 - | 4,540,601 +3% |
Mangement review
A significant improvement in the activities in the business areas resulting in higher than expected revenue.
Revenue and Profit
The company delivered a total revenue of DKK 2,727.4 million in financial year 2020/21 compared to DKK 2,039.5 million in the previous period. Financial year 2019/20 was considered to be a transition year due to the change of ownership and lower amount of manufacturing activities as well as a manufacturing maintenance slowdown and expenses related to the transition. In addition, it should be noted that the previous period covered a 15-month financial year due to the change in reporting period.
The growth in revenue was 34%, which exceeded expectations.
The revenue was negatively impacted throughout the year by USD exchange rates.
Profit before tax was DKK 132.8 million in the year compared to a loss of DKK 226.0 million in the previous year. The improvement can be attributed to the increased manufacturing activities in the drug substance area.
Net Profit
FDBD reported net profit of DKK 103.6 million in 2020/21 compared to a loss of DKK 176.3 million in 2019/20.
Investments
FDBD invested a total of DKK 473.4 million in tangible fixed assets in 2020/21. The investments are covering the operational capital investment to support the continuous manufacturing as well the expansion of the facility in building for the future project. COVID-19 was considered to have an impact in the earlier part of the year, but the company managed to pick up during the second half of the year.
Total assets increased in 2020/21. At year-end the total assets was DKK 5,848.4 million compared to the DKK 5,495.1 million the year before.
Equity
At the end of the financial year the equity shows DKK 3,865 million. The equity ratio decreased from 68.5% in 2019/20 to 66.1% in 2020/21.
Non-financial matters
Employees
We strive to be an attractive workplace, that can attract and retain the right employees with the right knowledge. This is essential to our current and future success.
At the end of 2020/21 the company had 881 full time employees, which was 133 employees more than the 748 employees the year before. This increase in employees is driven by increase in business activities and starting project related expansion activities on the site. All of the employees work from the company’s site in Hillerød.
Revenue and Profit
The company delivered a total revenue of DKK 2,727.4 million in financial year 2020/21 compared to DKK 2,039.5 million in the previous period. Financial year 2019/20 was considered to be a transition year due to the change of ownership and lower amount of manufacturing activities as well as a manufacturing maintenance slowdown and expenses related to the transition. In addition, it should be noted that the previous period covered a 15-month financial year due to the change in reporting period.
The growth in revenue was 34%, which exceeded expectations.
The revenue was negatively impacted throughout the year by USD exchange rates.
Profit before tax was DKK 132.8 million in the year compared to a loss of DKK 226.0 million in the previous year. The improvement can be attributed to the increased manufacturing activities in the drug substance area.
Net Profit
FDBD reported net profit of DKK 103.6 million in 2020/21 compared to a loss of DKK 176.3 million in 2019/20.
Investments
FDBD invested a total of DKK 473.4 million in tangible fixed assets in 2020/21. The investments are covering the operational capital investment to support the continuous manufacturing as well the expansion of the facility in building for the future project. COVID-19 was considered to have an impact in the earlier part of the year, but the company managed to pick up during the second half of the year.
Total assets increased in 2020/21. At year-end the total assets was DKK 5,848.4 million compared to the DKK 5,495.1 million the year before.
Equity
At the end of the financial year the equity shows DKK 3,865 million. The equity ratio decreased from 68.5% in 2019/20 to 66.1% in 2020/21.
Non-financial matters
Employees
We strive to be an attractive workplace, that can attract and retain the right employees with the right knowledge. This is essential to our current and future success.
At the end of 2020/21 the company had 881 full time employees, which was 133 employees more than the 748 employees the year before. This increase in employees is driven by increase in business activities and starting project related expansion activities on the site. All of the employees work from the company’s site in Hillerød.
30-08-2021